

Supplemental Information
For
VapA of *Rhodococcus equi* Binds Phosphatidic Acid

Lindsay M. Wright¹, Emily M. Carpinone², Terry L. Bennett², Mary K. Hondalus¹, and Vincent J. Starai^{1,2*}

¹Department of Infectious Diseases, University of Georgia, Athens, GA 30602

²Department of Microbiology, University of Georgia, Athens, GA 30602

*Corresponding Author:

Departments of Microbiology and Infectious Diseases

University of Georgia

Athens, GA 30602

vjstarai@uga.edu; telephone: 706-542-5755; fax: 706-542-2674

Keywords: *R. equi*, host-pathogen interactions, macrophage, phosphatidic acid, protein:lipid interaction

Table S1. Plasmids used in this study.

Plasmids	Description	Source
pHis-Parallel1	N-terminal His tag expression vector; Carb ^R	(Sheffield et al., 1999)
pGO35	yeast N-terminal GFP fusion expression plasmid	(Burd and Emr, 1998; Odorizzi et al., 1998)
pVapALMW	<i>vapA</i> (94-567) in pHis-Parallel1; Carb ^R	This Study
pVapGLMW	<i>vapG</i> in pHis-Parallel1; Carb ^R	This Study
pVapBLMW	<i>vapB</i> in pHis-Parallel1; Carb ^R	This Study
pVapK2LMW	<i>vapK2</i> in pHis-Parallel1; Carb ^R	This Study
pGFP-VapA	<i>vapA</i> in pGO35	This Study
pGFP-VapA ³²⁻¹⁸⁹	<i>vapA</i> (94-567) in pGO35	This Study
pGFP-VapG ²⁷⁻¹⁷²	<i>vapG</i> (79-519) in pGO35	This Study
pGFP-VapB ³⁵⁻¹⁹⁷	<i>vapB</i> (103-594) in pGO35	This Study
pGFP-VapK2 ³²⁻²⁰²	<i>vapK2</i> (94-609) in pGO35	This Study
pGFPmut2	constitutive GFP expression plasmid; Hyg ^R	(Burton et al., 2015)

Table S2. Primers used in this study.

Name	Sequence ¹	Plasmid Generated
VapA F (BamHI)	5'- <u>GTA</u> GGATCCGACCGTTCTTGATTCCGGTAG-3'	pVapALMW
VapA R (Sall)	5'-CTAGTCGACC <u>CCG</u> AAGTACGTGCAG-3'	pVapALMW
VapG F (EcoRI)	5'- <u>GAATTC</u> CGCGAAACTCAATGGTATCCAC-3'	pVapGLMW
VapG R (Spel)	5'-CTT <u>ACTAGT</u> TGAGTGCGCCGTCC-3'	pVapGLMW
VapB F (EcoRI)	5'-GTT <u>GAATT</u> CGCGGCTGTGCTGGATTTC-3'	pVapBLMW
VapB R (Sall)	5'-CAT <u>GT</u> CGACCTATGCGTTATGCAACCTC-3'	pVapBLMW
VapK2 F (EcoRI)	5'-GTT <u>GAATT</u> CCAACCGCTGGACGTTG -3'	pVapK2LMW
VapK2 R (Spel)	5'-CCT <u>ACTAGT</u> CGAACGTTATGTTGCC-3'	pVapK2LMW
GFP-VapA NSS F (BglII)	5'-ATGGATGA <u>ACTATA</u> CAAGTCCGGACTC <u>AGATCT</u> ATGACCGTTCTTGATTCCGGTAGC-3'	pGFP-VapA ³²⁻¹⁸⁹
GFP-VapA SS F (BglII)	5'-ATGGATGA <u>ACTATA</u> CAAGTCCGGACT <u>CAGATCT</u> ATGGTGAAGACTCTTCACAAGAC-3'	pGFP-VapA
GFP-VapA R (BglII)	5'-GTC <u>GA</u> CTGCAGAATT <u>CGAAGCTT</u> GAG <u>CTCGAGATCT</u> CTAGGC <u>GTG</u> TGCCAGCTAC-3'	pGFP-VapA ³²⁻¹⁸⁹ , pGFP-VapA
GFP-VapG NSS F (BglII)	5'-ATGGATGA <u>ACTATA</u> CAAGTCCGGACTC <u>AGATCT</u> ATGGAA <u>ACTT</u> CAATGGTATCCAC-3'	pGFP-VapG ²⁷⁻¹⁷²
GFP-VapG R (BglII)	5'-GTC <u>GA</u> CTGCAGAATT <u>CGAAGCTT</u> GAG <u>GCTCGAGATCT</u> TATTGCCACC <u>CTCCGG</u> TC-3'	pGFP-VapG ²⁷⁻¹⁷²
GFP-VapB NSS F (BglII)	5'-ATGGATGA <u>ACTATA</u> CAAGTCCGGACT <u>CAGATCT</u> ATGG <u>CTGTG</u> CTGGATTCCGGAGGC-3'	pGFP-VapB ³⁵⁻¹⁹⁷
GFP-VapB R (BglII)	5'-GTC <u>GA</u> CTGCAGAATT <u>CGAAGCTT</u> GAGC <u>TCGAGATCT</u> ATTATGCAAC <u>CTCCCAG</u> TTG-3'	pGFP-VapB ³⁵⁻¹⁹⁷

GFP-VapK2 NSS F (BglII)	5'-ATGGATGAACTATA <u>CAGATCT</u> ATGCAACCGCTGGACGTTG-3'	pGFP-VapK2 ³²⁻²⁰²
----------------------------	--	------------------------------

GFP-VapK2 R (BglII)	5'-GTCGACTGCAGAATT <u>TCGAGATCT</u> TATTATGACCAGCTGCCG-3'	pGFP-VapK2 ³²⁻²⁰²
------------------------	--	------------------------------

[†]Underlined sequence represents corresponding restriction site.

References

- Burd, C. G. and S. D. Emr (1998). Phosphatidylinositol(3)-phosphate signaling mediated by specific binding to RING FYVE domains. *Mol Cell* 2, 157-162.
- Burton, A.J., Giguere, S., Berghaus, L.J., Hondalus, M.K., and Arnold, R.D. (2015). Efficacy of liposomal gentamicin against *Rhodococcus equi* in a mouse infection model and colocalization with *R. equi* in equine alveolar macrophages. *Vet Microbiol* 176, 292-300.
- Odorizzi, G., M. Babst and S. D. Emr (1998). Fab1p PtdIns(3)P 5-kinase function essential for protein sorting in the multivesicular body. *Cell* 95, 847-858.
- Sheffield, P., S. Garrard and Z. Derewenda (1999). Overcoming expression and purification problems of RhoGDI using a family of "parallel" expression vectors. *Protein Expr Purif* 15, 34-39.




Figure S1. Proteinase K digestion of each recombinant Vap shows a stable protein core. 3 µg of indicated recombinant Vap protein was incubated with or without Proteinase K (500:1 protein:Proteinase K molar ratio) and, where indicated, 1% SDS for 75 min at 37 °C. Reactions were separated via SDS-PAGE and stained with Coomassie Brilliant Blue. The asterisk (*) indicates the dye front of the gel.